GenSight Biologics Valuation
| GSGTF Stock | USD 0.19 0.00 0.00% |
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. GenSight Biologics regular Real Value cannot be determined due to lack of data. The prevalent price of GenSight Biologics is $0.19. Our model calculates the value of GenSight Biologics from evaluating the firm fundamentals such as Return On Equity of -1.72, return on asset of -0.39, and Shares Outstanding of 46.16 M as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that GenSight Biologics' price fluctuation is out of control at this time. Calculation of the real value of GenSight Biologics is based on 3 months time horizon. Increasing GenSight Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the GenSight pink sheet is determined by what a typical buyer is willing to pay for full or partial control of GenSight Biologics SA. Since GenSight Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GenSight Pink Sheet. However, GenSight Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.19 | Real 0.0 | Hype 0.0 | Naive 0.19 |
The real value of GenSight Pink Sheet, also known as its intrinsic value, is the underlying worth of GenSight Biologics Company, which is reflected in its stock price. It is based on GenSight Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of GenSight Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of GenSight Biologics SA helps investors to forecast how GenSight pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GenSight Biologics more accurately as focusing exclusively on GenSight Biologics' fundamentals will not take into account other important factors: GenSight Biologics Total Value Analysis
GenSight Biologics SA is currently anticipated to have takeover price of 131.61 M with market capitalization of 162.24 M, debt of 5.64 M, and cash on hands of 24.15 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the GenSight Biologics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
131.61 M | 162.24 M | 5.64 M | 24.15 M |
GenSight Biologics Investor Information
About 13.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.67. GenSight Biologics had not issued any dividends in recent years. Based on the key indicators related to GenSight Biologics' liquidity, profitability, solvency, and operating efficiency, GenSight Biologics SA is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.GenSight Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. GenSight Biologics has an asset utilization ratio of 9.31 percent. This implies that the Company is making $0.0931 for each dollar of assets. An increasing asset utilization means that GenSight Biologics SA is more efficient with each dollar of assets it utilizes for everyday operations.GenSight Biologics Ownership Allocation
GenSight Biologics SA has a total of 46.16 Million outstanding shares. 30% of GenSight Biologics outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.GenSight Biologics Profitability Analysis
The company reported the revenue of 5.28 M. Net Loss for the year was (28.62 M) with profit before overhead, payroll, taxes, and interest of 7.71 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates GenSight Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in GenSight Biologics and how it compares across the competition.
About GenSight Biologics Valuation
The pink sheet valuation mechanism determines GenSight Biologics' current worth on a weekly basis. Our valuation model uses a comparative analysis of GenSight Biologics. We calculate exposure to GenSight Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GenSight Biologics's related companies.GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France. Gensight Biologics is traded on OTC Exchange in the United States.
8 Steps to conduct GenSight Biologics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates GenSight Biologics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct GenSight Biologics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain GenSight Biologics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine GenSight Biologics' revenue streams: Identify GenSight Biologics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research GenSight Biologics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish GenSight Biologics' growth potential: Evaluate GenSight Biologics' management, business model, and growth potential.
- Determine GenSight Biologics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate GenSight Biologics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
GenSight Biologics Growth Indicators
Investing in growth stocks can be very risky. If the company such as GenSight Biologics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 46.2 M | |
| Retained Earnings | -28.6 M |
Complementary Tools for GenSight Pink Sheet analysis
When running GenSight Biologics' price analysis, check to measure GenSight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GenSight Biologics is operating at the current time. Most of GenSight Biologics' value examination focuses on studying past and present price action to predict the probability of GenSight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GenSight Biologics' price. Additionally, you may evaluate how the addition of GenSight Biologics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets |